Lomefloxacin hydrochloride is a fluoroquinolone antibiotic used to treat bacterial infections, including bronchitis and urinary tract infections (UTIs). It is also used to prevent urinary tract infections prior to surgery. Lomefloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication and repair, which leads to bacterial cell death. While effective against a range of bacterial pathogens, Lomefloxacin is associated with phototoxicity and central nervous system adverse effects, necessitating caution in sun exposure and use in susceptible patients.
Parent: Lomefloxacin
Parent: Lomefloxacin
Parent: Lomefloxacin
Parent: Lomefloxacin
During the production and storage of Lomefloxacin, impurities may form, which must be controlled to ensure the medication’s safety and efficacy. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provide guidelines on permissible impurity levels in Lomefloxacin formulations.
Lomefloxacin is used to treat bacterial infections, primarily urinary tract infections (UTIs) and respiratory infections such as bronchitis. Its broad-spectrum activity makes it effective against a range of bacterial pathogens. It is also prescribed to prevent UTIs prior to surgery.
Lomefloxacin is a second-generation fluoroquinolone antibiotic, known for its activity against gram-negative bacteria and improved pharmacokinetic properties compared to earlier quinolones.
Lomflox is a brand name for Lomefloxacin, and it is used to treat bacterial infections, especially UTIs and respiratory infections. Lomflox is effective in managing infections caused by bacteria sensitive to Lomefloxacin.
The half-life of Lomefloxacin is approximately 8 to 9 hours, allowing for once or twice-daily dosing in most cases. The extended half-life also enables Lomefloxacin to maintain effective concentrations in the body for bacterial eradication.
